Responses
Oncolytic and local immunotherapy
Original research
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.